Press | Visionology

Visionology Acquires License to SPARCS

Visionology, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its SPARCS technology available on Visionology’s direct-to-consumer eyecare platform, Visionology.com.

Klarity-C Dry Eye Treatment with Topical Cyclosporine 0.1%

This retrospective multicenter study included 100 eyes of 50 dry eye patients aged ≥18 years, with preoperative ocular surface disease index (OSDI) score >12 or corneal staining grade >1 (in either eye) who underwent dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate emulsion (Klarity-C, ImprimisRx) for 3 months.

Important Notice regarding Klarity-C

During the September 27, 2019 Board of Optometry meeting, the Board approved Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002, Florida Administrative Code – Formulary of Topical Pharmaceutical Agents.